# Medicinal Cannabis Goes Mainstream but Australia Struggles to Cope > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabinoid-clinical-research-excellence-australia/ > **Published:** 2026-03-25T21:30:35-04:00 | **Last Modified / Clinically Audited:** 2026-09-29T00:17:20-04:00 > **Clinical Summary:** Explore how the Cannabinoid Clinical Research Excellence centre addresses Australia's medicinal cannabis challenges with evidence-based clinical guidance. --- ✦ New CED Clinical Relevance #72 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. PolicyResearchSafetyIndustry Why This Matters As medicinal cannabis prescribing increases in Australia, clinicians need clear evidence-based guidance and institutional support to safely counsel patients on efficacy, dosing, and drug interactions for specific conditions. The establishment of the Cannabinoid Clinical and Research Excellence centre addresses a critical gap by consolidating research and best practices, enabling clinicians to move beyond anecdotal reports to evidence-informed prescribing decisions. Patients benefit when their clinicians have access to standardized training and reliable information rather than navigating conflicting claims about [cannabis safety](https://cedclinic.com/respiratory-effects-inhalational-marijuana/) and therapeutic benefit. Clinical Summary Australia’s medicinal cannabis sector is expanding rapidly following regulatory approval, but the healthcare system lacks adequate infrastructure and expertise to manage this growth effectively, as evidenced by the establishment of the Cannabinoid Clinical and Research Excellence (ACRE) center with NHMRC funding to address knowledge gaps. The mainstream adoption of cannabis-based medicines has outpaced clinician training, standardized prescribing protocols, and quality assurance mechanisms, creating challenges in ensuring safe and evidence-based patient care across the country. Without sufficient clinical guidance and research capacity, Australian practitioners face barriers to appropriate patient selection, dosing, and monitoring of cannabis therapies, while patients may encounter inconsistent care quality and access disparities. The ACRE initiative represents an attempt to systematize knowledge and establish best practices, but resource constraints and the nascent state of medicinal [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) suggest that many clinicians remain underprepared to manage this therapeutic option. For Australian clinicians and patients, the key takeaway is that while medicinal cannabis is now legally available, accessing treatment through informed practitioners supported by robust clinical standards remains a work in progress, making engagement with emerging evidence-based centers and protocols essential until broader expertise develops. Dr. Caplan’s Take “We have more patients asking about cannabis than we have evidence to guide them, and that’s the real clinical problem we’re facing right now. Australia’s investment in ACRE is exactly what we need because without rigorous research infrastructure, we’re essentially asking physicians to prescribe based on anecdote rather than pharmacology, which ultimately fails our patients.” Clinical Perspective As medicinal cannabis access expands across Australia through regulatory pathways like the Special Access Scheme, clinicians increasingly encounter patients seeking or already using these products for conditions ranging from chronic pain to epilepsy. While the establishment of dedicated research centers signals growing institutional recognition of cannabinoids’ therapeutic potential, the current evidence base remains heterogeneous, with robust data limited to specific indications such as chemotherapy-induced nausea and certain seizure disorders. The gap between patient demand, regulatory availability, and clinical evidence creates a challenging landscape where providers must weigh potential benefits against incomplete safety and efficacy profiles, uncertain dosing standards, and variable product quality. Clinicians should approach medicinal cannabis discussions with informed curiosity rather than dismissal, document their reasoning for any prescribing or recommendation decisions, and consider referring complex cases to emerging cannabinoid specialists where available, while maintaining awareness that current evidence does not support routine use across most indications. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/cannabis-industry/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Medicinal+cannabis+has+gone+mainstream.+But+Australia%27s+struggling+to+cope+-+The+Conversation+%40drcaplan&url=https%3A%2F%2Ftheconversation.com%2Fmedicinal-cannabis-has-gone-mainstream-but-australias-struggling-to-cope-271744)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Ftheconversation.com%2Fmedicinal-cannabis-has-gone-mainstream-but-australias-struggling-to-cope-271744)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Medicinal+cannabis+has+gone+mainstream.+But+Australia%27s+struggling+to+cope+-+The+Conversation+--+via+%40drcaplan.bsky.social+https%3A%2F%2Ftheconversation.com%2Fmedicinal-cannabis-has-gone-mainstream-but-australias-struggling-to-cope-271744)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Related Articles - [Medicinal cannabis has gone mainstream. But Australia’s struggling to cope – Crikey](https://cedclinic.com/australian-medical-cannabis-program-challenges/) - Medicinal cannabis has gone mainstream. But Australia’s struggling to cope – The Conversation - [CED Digest: 436 Items — March 14, 2026](https://cedclinic.com/cannabis-compounds-fatty-liver-disease-2026/) 📰 Source: [https://theconversation.com/medicinal-cannabis-has-gone-mainstream-but-australias-struggling-to-cope-271744](https://theconversation.com/medicinal-cannabis-has-gone-mainstream-but-australias-struggling-to-cope-271744) Further Reading Research Digest[Research Digest: 5 Recent Studies – March 25, 2026](https://cedclinic.com/research-digest-recent-studies-march-2026/) CED Clinic Blog[Certificates of analysis, how patients can read between the lines #4](https://cedclinic.com/certificate-of-analysis-cannabis-safety/) Cannabis Policy Wire[Policy Watch: 20 Regulatory Updates — March 20, 2026](https://cedclinic.com/drug-enforcement-controlled-substances-regulatory-policy-2026/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Cannabis research](https://cedclinic.com/pediatric-cannabis-certification-care-children/) is more than a scientific pursuit—it's a pathway to better health, informed … Discover how cannabis research is evolving to improve health outcomes and inform clinical practice. Learn More [Q&A: What does science say about plants as medicine?](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) Explore scientific perspectives on medicinal plants including cannabis and their therapeutic potential. [Read Q&A](https://cedclinic.com/qa-what-does-science-say-about-plants-as-medicine/) [The Science Behind Cannabis: Latest Health Studies](https://cedclinic.com/the-science-behind-cannabis-latest-health-studies/) Stay updated on the latest scientific studies exploring cannabis health effects and clinical applications. [Explore Studies](https://cedclinic.com/the-science-behind-cannabis-latest-health-studies/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).